Of note, cyclopamine treatment significantly decreased the integration of the GFP+ BM-derived pro-angiogenic cells (BMPCs) into CD31+, VE-cadherin+, or NG2+ tumor vasculatures. This evidence concerns the gene PECAM1 and neoplasm.